Table 4. Frequency of medication use according to drug class and time that had elapsed since coronary heart disease, at baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
| Drug class and combination |
|
Total | |||
|---|---|---|---|---|---|
| ≤ 4 | 5-9 | 10-14 | ≥ 15 | ||
| Only ASA/other antiplatelet | 3 (1.8) | 4 (3.5) | 1 (1.5) | 1 (2.2) | 9 (2.3) |
| Only beta blocker | 3 (1.8) | 6 (5.3) | 2 (2.9) | 1 (2.2) | 12 (3.0) |
| Only ACEI/ARB | 7 (4.1) | 3 (2.7) | 8 (11.8) | 6 (13.0) | 24 (6.0) |
| Only statin/fibrate | 7 (4.1) | 5 (4.4) | 1 (1.5) | 2 (4.3) | 15 (3.8) |
| ASA/other antiplatelet + beta blocker | 2 (1.2) | 1 (0.9) | 3 (4.4) | 1 (2.2) | 7 (1.8) |
| ASA/other antiplatelet + ACEI/ARB | 6 (3.5) | 2 (1.8) | 3 (4.4) | 1 (2.2) | 12 (3.0) |
| ASA/other antiplatelet + statin/fibrate | 10 (5.8) | 9 (8.0) | 6 (8.8) | 1 (2.2) | 26 (6.5) |
| Beta blocker + ACEI/ARB | 7 (4.1) | 3 (2.7) | 2 (2.9) | 1 (2.2) | 13 (3.3) |
| Beta blocker + statin/fibrate | 4 (2.3) | 2 (1.8) | 2 (2.9) | 1 (2.2) | 9 (2.3) |
| ACEI/ARB + statin/fibrate | 7 (4.1) | 5 (4.4) | 1 (1.5) | 1 (2.2) | 14 (3.5) |
| ASA/other antiplatelet + beta blocker + ACEI/ARB | 6 (3.5) | 4 (3.5) | 4 (5.9) | 3 (6.5) | 17 (4.3) |
| ASA/other antiplatelet + beta blocker + statin/fibrate | 20 (11.7) | 16 (14.2) | 8 (11.8) | 5 (10.9) | 49 (12.3) |
| ASA/other antiplatelet + ACEI/ARB + statin/fibrate | 12 (7.0) | 6 (5.3) | 2 (2.9) | 1 (2.2) | 21 (5.3) |
| Beta blocker + ACEI/ARB + statin/fibrate | 5 (2.9) | 7 (6.2) | 1 (1.5) | 3 (6.5) | 16 (4.0) |
| ASA/other antiplatelet + beta blocker + ACEI/ARB + statin/fibrate | 42 (24.6) | 26 (23.0) | 14 (15.2) | 10 (21.7) | 92 (23.1) |
| None of the recommended drugs | 30 (17.5) | 14 (12.4) | 10 (14.7) | 8 (17.4) | 62 (15.6) |
| Total | 171 (100) | 113 (100) | 68 (100) | 46 (100) | 398 (100) |
CHD = coronary heart disease; ASA = acetylsalicylic acid; ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers.